Hormone Resistant Prostate Cancer Completed Phase 1 / 2 Trials for Enzalutamide (DB08899)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02555189Enzalutamide With Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB ExpressionTreatment
NCT02012296Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate CancerTreatment